Hot flashes don't last just a few months. In the large American SWAN study, which followed 3,302 women, those who experienced them frequently kept them for 7.4 years in median, and still 4.5 years after their last period.
This comparison ranks the best-selling supplements, from soy to saffron, according to studies identified via PubMed: trial size, actual difference from placebo, form and dose tested, safety. It also maps medical options and proposes a selection method.
Hot flashes : soy isoflavones have the best documented effect size among supplements, with 20.6% fewer hot flashes than placebo in a meta-analysis of 17 trials, a modest and variable effect from one trial to another. Red clover, sage, hops and pollen are based on smaller or weaker trials; black cohosh performs no better than placebo. Hormone therapy remains the most effective, and should be discussed with your doctor, as with non-hormonal medications.
Mood, sleep, bones, skin : saffron and ashwagandha improved mood or overall symptom score in trials of 6 to 12 weeks, maca in very small trials. Melatonin mainly helps women who already sleep poorly. For bones, the combination of calcium and vitamin D reduced fracture risk, not vitamin D alone. Omega-3 and magnesium did not reduce hot flashes.
- What we're trying to relieve, and the placebo trap
- Hormone therapy and non-hormonal medications
- The comparison: each active ingredient ranked by level of evidence
- Soy isoflavones: the most studied
- Red clover and kudzu, other sources of isoflavones
- Sage and hops: encouraging but small trials
- Black cohosh, evening primrose, pollen: disappointing results
- Mood and sleep: saffron, ashwagandha, maca, melatonin
- Bones, skin and mucous membranes: vitamin D, calcium, collagen
- Safety: medical history, liver and cumulative interactions to avoid
- Choose based on your main symptom
- Frequently asked questions
What we seek to relieve, and the placebo trap
Menopause is not a disease: it is a life stage that some women go through with almost no discomfort and others with marked symptoms. The most common are hot flashes and night sweats, then sleep disturbances, mood changes, fatigue, vaginal dryness and, in the long term, bone loss. Our menopause guide details these symptoms and their timeline.
Their duration varies greatly. In the SWAN cohort, women who had their first frequent hot flashes before or at the very beginning of perimenopause kept them for more than 11.8 years in median, compared to 3.4 years for those in whom they appeared after menopause. Signs of perimenopause therefore deserve to be taken seriously from the start.
In an American trial, 354 participants had to rank the symptoms they wanted to relieve first: hot flashes came first (322 cited them), ahead of sleep (191), concentration (140) and fatigue (116). This is the first question to ask yourself.
In trials of phytoestrogens, placebo alone reduced hot flash frequency by 1% to 59% depending on the trial. Out of 43 randomized trials involving 4,364 women, the authors found no conclusive evidence of an effect of phytoestrogen supplements overall, while considering that extracts concentrated in genistein merit further study.
Lethaby A, Marjoribanks J, Kronenberg F, et al. Cochrane Database Syst Rev 2013;(12):CD001395. DOI: 10.1002/14651858.CD001395.pub4
Hot flashes fluctuate and often decrease over time: only the difference from placebo in randomized trials counts here.
Hormone therapy and non-hormonal medications
<<<37>>> Menopausal hormone therapy traitement hormonal de la ménopause remains, according to the 2022 position of the North American Menopause Society, the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and it prevents bone loss and fractures. Its risks depend in particular on the type of hormones, dose, route of administration and when it is started. For women under 60 years old or menopause for less than 10 years, without contraindication, the benefit-risk balance is considered favorable; it is less so beyond that, due to higher absolute risks of coronary disease, stroke, venous thrombosis and dementia.
For women who cannot or do not wish to take hormones, the 2023 position of the same society recommends, with the highest level of evidence, cognitive-behavioral therapy, clinical hypnosis, certain antidepressants (serotonin reuptake inhibitors, or serotonin and noradrenaline reuptake inhibitors), gabapentin, and fezolinetant. Conversely, it does not recommend herbal supplements and remedies for hot flashes (level of evidence I to II), nor soy in food or extract form, nor equol (limited or inconsistent evidence).
In 899 women experiencing at least 14 hot flashes per week, low-dose oral estradiol (0.5 mg per day) reduced hot flash frequency by 2.4 per day more than placebo after 8 weeks, venlafaxine by 1.8, and escitalopram by 1.4. Aerobic exercise, yoga, and 1.8 g of omega-3 per day had no effect on frequency or severity.
Guthrie KA, LaCroix AZ, Ensrud KE, et al. Obstet Gynecol 2015;126(2):413-422. DOI: 10.1097/AOG.0000000000000927
Fezolinetant acts on a brain receptor involved in temperature control. In the SKYLIGHT 1 trial, funded by its manufacturer, 527 women aged 40 to 65 years experiencing an average of at least 7 moderate to severe hot flashes per day were divided into three groups: at 12 weeks, doses of 30 and 45 mg reduced hot flash frequency by 2.39 and 2.55 per day more than placebo. These options should be chosen with your doctor.
The comparison: each active ingredient ranked by level of evidence
Level of evidence takes into account the number, size, and duration of trials, the presence of a placebo, and the consistency of results. A result obtained with a standardized extract does not apply to a plant powder.
| Active ingredient | Symptom studied | What the trials show | Level of evidence |
|---|---|---|---|
| Soy isoflavones (extracts) | Hot flashes | −20.6% frequency, −26.2% severity | Moderate, meta-analysis of 17 trials |
| Red clover (extracts) | Hot flashes | −1.73 hot flash per day; not significant in another meta-analysis | Weak to moderate, discordant results |
| Kudzu (root) | Overall symptom score | Score decreased, without placebo group | Very weak |
| Sage (leaf extracts) | Hot flashes, night sweats | More responders than with placebo | Weak, small trials |
| Hops (extract standardized to 8-PN) | Hot flashes, overall score | Superior to placebo at 6 weeks, not at 12 | Weak, 2 small trials |
| Black cohosh | Hot flashes | No difference with placebo | Mild to moderate, with no demonstrated effect |
| Evening primrose oil | Hot flashes | Severity slightly reduced, neither frequency nor duration affected | Mild |
| Pollen extracts | Hot flashes | Not significant when controlled studies are pooled | Very mild |
| Saffron (extracts) | Mood, anxiety | Psychological symptoms improved | Mild to moderate |
| Ashwagandha (root extract) | Overall perimenopausal score | Symptom score reduced | Mild, one trial |
| Maca (root powder) | Mood, libido | Favorable effects in 4 small trials | Very mild |
| Melatonin | Sleep | Better in women with poor sleep | Mild to moderate |
| Calcium and vitamin D | Fractures | −15% reduction in fractures; vitamin D alone with no effect | Moderate |
| Hydrolyzed collagen | Skin | Hydration, elasticity, wrinkles improved | Moderate, 19 trials |
| Omega-3, magnesium | Hot flashes | No effect versus placebo | Moderate, unfavorable |
Soy isoflavones: the most studied
Isoflavones, or phytoestrogens, are plant compounds with a structure similar to estrogens; soy contains mainly genistein and daidzein.
In women in perimenopause and after menopause, soy isoflavones extracted or synthesized, at a median dose of 54 mg per day expressed as aglycones, taken for 6 weeks to 12 months, reduced the frequency of hot flashes by 20.6% and their severity by 26.2% compared to placebo. Supplements providing more than 18.8 mg of genistein were more than twice as effective on frequency than those providing less.
Taku K, Melby MK, Kronenberg F, et al. Menopause 2012;19(7):776-790. DOI: 10.1097/gme.0b013e3182410159
Two caveats are necessary. Results vary greatly from one trial to another: heterogeneity reached 67% for frequency and 86% for severity; some trials find a clear effect, others almost none. The Cochrane review, more cautious, was unable to pool most soy trials; however, it notes that the four trials using genistein-rich extracts, more than 30 mg per day, consistently reduced the frequency of hot flashes.
Over time, an Italian trial warrants caution. In 376 postmenopausal women with an intact uterus, 150 mg of soy isoflavones per day for 5 years were associated with 3.37% endometrial hyperplasia, an abnormal thickening of the uterine lining, versus none under placebo; no cancer was detected. The dose was considerably higher than the median of the trials, but this result justifies not prolonging isoflavone supplementation indefinitely without medical advice.
For bone, the effect is modest. In a crossover trial in 11 postmenopausal women, soy cotyledon isoflavones reduced net bone resorption by 9% in 50 days, those from soy germ by 5%, compared to 22 to 24% for an osteoporosis drug and for hormone therapy. Isoflavones from kudzu and red clover tested in the same trial had no significant effect.
Trials often express the dose in aglycones, the free form of isoflavones, while foods and some extracts contain them mainly in a form bound to sugar (glycosides), heavier. The same displayed quantity can therefore correspond to different active doses. The genistein content is the most useful reference point.
Red clover and kudzu, other sources of isoflavones
For red clover, a meta-analysis of 8 trials published in 2021 finds 1.73 fewer hot flashes per day than with placebo, with a wide confidence interval (0.18 to 3.28 hot flashes) and high heterogeneity. The difference was more marked in postmenopausal women with at least 5 hot flashes per day, after 12 weeks, at 80 mg of isoflavones per day or more. The Cochrane review, which had pooled 5 trials conducted with the same red clover extract, found no significant difference (0.93 fewer hot flashes per day, interval consistent with no effect).
The kudzu (Pueraria montana var. lobata, long called Pueraria lobata) is a plant from Chinese pharmacopoeia whose root contains puerarin, daidzin and daidzein. Clinical data are scarce, as detailed in our article on kudzu and menopause.
Fifty postmenopausal women took an ethanolic extract of kudzu root for 4 weeks, 0.84 to 2.52 g per day depending on the group (113 to 338 mg of puerarin). The menopause symptom score decreased in 4 out of 5 groups, down to 7.1 points out of 44, and bone resorption markers decreased. The trial had no placebo group, which the authors present as its main limitation, and it was funded by a research company affiliated with the authors.
Bihlet AR, Byrjalsen I, Andersen JR, et al. Front Pharmacol 2021;12:760629. DOI: 10.3389/fphar.2021.760629
An earlier trial in 127 postmenopausal women, comparing over 3 months a kudzu root preparation providing 100 mg of isoflavones per day with hormone therapy and no treatment, had not shown net benefit on symptoms or on a bone resorption marker. In the 2021 trial, 90% of participants reported an adverse effect, most often mild, especially headaches (30%). They were advised to avoid alcohol, as antabuse-like effects have been reported with kudzu root. See also clinical studies of kudzu.
Our Kudzu provides 750 mg of root for two capsules; its isoflavone content is not indicated, and the 2021 trial used an ethanolic extract dosed in puerarin: the quantities are therefore not comparable. It is not recommended for women with a personal or family history of breast cancer, during pregnancy and breastfeeding, and in case of hormone-dependent disorder (cancers of the uterus, ovaries or prostate, endometriosis, fibroids). See our article on side effects of kudzu.
Sage and hops: encouraging but small trials
The common sage (Salvia officinalis) has long been used against excessive sweating. A 2023 meta-analysis combined 4 studies and 310 menopausal women: it concluded that there was a decrease in hot flash frequency compared to placebo, but based on only 3 studies that were highly heterogeneous, and the confidence interval (−2.37 to 0.14) includes the possibility of no effect; the effect on severity was not significant. The result is therefore not established.
Eighty menopausal women aged 48 to 65, experiencing at least 5 hot flashes per day or intense daily hot flashes, took for 4 weeks tablets of fresh sage leaf extract without thujone (280 mg of extract per tablet) or placebo. In the main analysis conducted on 48 women, 59.1% saw their hot flash score decrease by at least half, compared to 26.9% on placebo; among all participants, 55% versus 32.5%. The trial was funded by the extract manufacturer, whose employee is a co-author of the article.
Dimpfel W, Chiegoua Dipah GN, Bommer S. Heliyon 2021;7(2):e05910. DOI: 10.1016/j.heliyon.2021.e05910
An Iranian double-blind trial in 66 menopausal women, taking 3 tablets daily of 100 mg sage extract for 3 months, also found a decrease in hot flash score compared to placebo, as well as improved sleep score in the sage group. An older Swiss trial in 71 women taking one tablet of fresh sage leaves daily for 8 weeks reported 64% reduction in hot flash score, but without a placebo group and with an author linked to the manufacturer: this figure cannot be interpreted as the effect of sage alone.
The hops (Humulus lupulus) contain 8-prenylnaringenin, or 8-PN, a potent phytoestrogen. In a 12-week Belgian trial in 67 menopausal women, a standardized extract providing 100 µg of 8-PN daily was superior to placebo at 6 weeks, but not at 12 weeks, and the 250 µg dose was no better than the lower dose. A second crossover trial in 36 women at 100 µg daily showed no significant overall effect, with favorable results only in the second treatment period.
Our Menopause Bio combines hops (480 mg), sage (390 mg), lemon balm (300 mg), maca (300 mg), and black currant (100 mg) in three capsules. No trial has tested this formula, and the form of its plants (powder or extract) and their standardization are not specified: its quantities cannot be compared to the 280 mg of sage extract or the 100 µg of 8-PN from these studies. It is used at the stated dose, without long-term use, and is not recommended for women with a personal or family history of breast cancer.
Black cohosh, evening primrose, pollen: disappointing results
Theblack cohosh (Cimicifuga racemosa, also called Actaea racemosa) is one of the most studied plants for menopause. The 2012 Cochrane review combined 16 randomized trials and 2,027 women, at a median dose of 40 mg daily for an average of 23 weeks. It found no difference with placebo on hot flash frequency (0.07 more hot flashes per day, interval −0.43 to 0.56; 3 trials, 393 women) or on symptom scores, while hormone therapy performed better than black cohosh.
It also raises a liver safety concern: in a survey of published cases of liver damage linked to plants and supplements over 50 years, black cohosh ranked second among plants by number of publications, behind germander. Causality remains debated: in an analysis of 573 cases of liver damage initially attributed to plants, including black cohosh, another cause was found in 48.5% of cases (virus, autoimmune disease, associated medication). As a precaution, any unusual fatigue, dark urine, or jaundice requires stopping treatment and consulting a doctor.
Theevening primrose oil is rich in gamma-linolenic acid. A 2024 meta-analysis found hot flash severity slightly lower than placebo for durations under 6 months, but no difference in their frequency or duration; reported adverse effects were mild nausea and headaches. In a trial in 56 women over 6 weeks, only severity improved more than placebo (42% versus 32% improvement). Our Organic evening primrose and borage oil combines 500 mg evening primrose oil, 500 mg borage oil, and 10 mg vitamin E per two capsules (capsule of porcine origin): this is a different formula from the evening primrose oil alone tested in these trials. See our article onevening primrose and borage oil.
The purified pollen extracts have one positive randomized trial: in 64 women, 65% saw their hot flashes decrease compared to 38% on placebo after 3 months, with 27% fewer hot flashes than in the placebo group according to symptom diaries. But a 2024 meta-analysis, combining one randomized trial and 4 observational studies (420 women), notes that the improvement disappears when only controlled studies are grouped together, and suggests that part of the observed effect stems from placebo.
Mood and sleep: saffron, ashwagandha, maca, melatonin
Saffron. In an Australian 12-week trial in 86 perimenopausal women, a standardized saffron extract at 14 mg twice daily reduced psychological symptoms more than placebo, with 33% less anxiety and 32% fewer depressive symptoms compared to baseline; it performed no better than placebo on hot flashes. In an Iranian 6-week trial in 60 menopausal women suffering from both hot flashes and a major depressive episode, 30 mg saffron daily improved both hot flash-related discomfort and depression score. See also our article on saffron and sleep.
Ashwagandha. An Indian 8-week trial in 100 perimenopausal women compared 300 mg of root extract twice daily to placebo: the total menopausal symptom score decreased markedly, in its psychological, somatic, and urogenital components, and blood estradiol increased. This is a single trial. Liver damage has also been described elsewhere, including a series of 5 cases from Iceland and the United States with jaundice appearing after 2 to 12 weeks, normalized within 1 to 5 months in 4 patients. See our article on ashwagandha precautions.
Maca. A 2011 systematic review found only 4 randomized trials, all favorable but too small and of too limited quality to conclude. The most cited, a crossover trial in 14 postmenopausal women with 3.5 g of maca powder daily for 6 weeks, reduced anxiety, depressive symptoms, and sexual difficulties compared to placebo, without changing blood hormones. Our article on maca covers these findings.
Melatonin. A systematic review of 24 studies (1,173 participants) concludes that melatonin improves subjective sleep quality in postmenopausal women who already slept poorly, and that from 3 mg onwards it improves certain menopausal symptoms; it also notes a possible increase in triglycerides. In 41 healthy postmenopausal women whose sleep was poor at baseline, 10 mg daily for 3 months did not improve sleep quality compared to placebo. Our Optimal Sleep provides, per capsule, 1.9 mg of melatonin with lemon balm (100 mg), hops (100 mg), passionflower (50 mg), and valerian (50 mg); it is not recommended before age 12.
Bones, skin, and mucous membranes: vitamin D, calcium, collagen
The decline in estrogen accelerates bone loss. A meta-analysis of 8 randomized trials (30,970 participants), conducted for an American osteoporosis foundation, finds that the combination calcium and vitamin D reduces fracture risk by 15% and hip fracture risk by 30%. Conversely, a meta-analysis of 81 trials shows that vitamin D alone does not reduce fractures or falls, and does not clinically meaningfully change bone density, regardless of dose.
Vitamin D retains its value for correcting a deficiency, which should be verified by a blood test (see our article on vitamin D deficiency). Our Plant-Based Vitamin D3 provides 1,000 IU per drop, at 2 drops daily for adults; calcium intake should primarily come from diet.
For skin, which thins and dries with declining estrogen, a meta-analysis of 19 double-blind randomized trials (1,125 participants aged 20 to 70, 95% women) shows that hydrolyzed collagen improves hydration, elasticity, and wrinkles compared to placebo, with intake for approximately 90 days. Our Marine Collagen and Hyaluronic Acid in Capsules provides, per 4 capsules, 1,208 mg of marine collagen, 200 mg of hyaluronic acid, and 160 mg of vitamin C; trials used varied products and doses, detailed in our article on collagen and skin.
Genitourinary syndrome of menopause, including vaginal dryness, affects an estimated 27 to 84% of postmenopausal women. Over-the-counter vaginal lubricants and moisturizers usually suffice for mild discomfort; for moderate to severe discomfort, low-dose vaginal estrogens and other treatments are effective and are prescribed after discussion with your doctor.
Finally, omega-3, at 1.8 g daily, did not reduce hot flashes in the MsFLASH trials. Neither did magnesium : in a randomized trial of 289 postmenopausal women with a history of breast cancer, magnesium oxide at 800 or 1,200 mg daily performed no better than placebo, with more diarrhea.
Safety: medical history, liver, and duplicate combinations to avoid
Phytoestrogens act weakly on estrogen receptors. Cochrane review trials excluded women with a history of breast cancer: data are lacking in this population.
Personal or family history of breast cancer, or hormone-dependent disease (uterine or ovarian cancer, endometriosis, fibroids): no phytoestrogen-based supplement (soy, red clover, kudzu, hops) without your doctor's approval; our Menopause Bio is not recommended if you have a personal or family history of breast cancer, our Kudzu in all of these situations. Liver disease : medical advice before black cohosh or ashwagandha, and immediate discontinuation in case of jaundice, dark urine, or unusual fatigue. Pregnancy and breastfeeding : kudzu is not recommended, and pregnancy remains possible during perimenopause; seek advice before taking any herbal product. Current treatment (antidiabetic, anticoagulant, antihypertensive, antidepressant, hormones): consult your doctor or pharmacist. Prolonged use : 150 mg of isoflavones per day for 5 years have been associated with endometrial hyperplasia; review regularly.
The combinations are the other pitfall: our Optimal Sleep also contains hops (100 mg per capsule) and lemon balm (100 mg), our Organic Maca provides 1.28 g of root per 4 capsules and our Female Libido 580 mg of maca per 3 capsules, plants already present in Menopause Bio. Combining multiple sources of phytoestrogens has not been studied.
| Association | What accumulates | Advice |
|---|---|---|
| Menopause Bio and Kudzu | Hops and kudzu isoflavones, two sources of phytoestrogens | Choose one or the other, or consult your doctor |
| Menopause Bio and Optimal Sleep | Hops and lemon balm present in both | Avoid combining them without professional advice |
| Menopause Bio and Organic Maca or Female Libido | Maca present in both | Add the maca doses, do not combine them by default |
| Soy and red clover or kudzu isoflavones | Multiple sources of isoflavones | One source at a time |
Choose according to your main symptom
If your symptoms disrupt your sleep, work, or intimate life, discuss this first with your doctor.
According to the 2023 position already cited, cognitive-behavioral therapy and clinical hypnosis are among the best-supported approaches, and weight loss is also among the options. Our practical tips against hot flashes complement this comparison.
Five plants from organic farming, in vegetable capsules : hops, sage, lemon balm, maca and blackcurrant. Three capsules per day, with a large glass of water during meals, provide 480 mg of hops, 390 mg of sage, 300 mg of lemon balm, 300 mg of maca and 100 mg of blackcurrant.
View Organic MenopausePrefer a single plant? Discover our Kudzu, 750 mg of root for two capsules.
Frequently asked questions
What is the best supplement for menopause?
It all depends on the main symptom and medical history. For hot flashes, soy isoflavones have the best measured effect, approximately 20% fewer flashes than with placebo. For mood, saffron has the most favorable trials.
Which dietary supplement is effective against hot flashes?
Soy isoflavones reduced the frequency of hot flashes by 20.6% and their severity by 26.2% compared to placebo in a meta-analysis of 17 trials. Sage, red clover and hops have smaller trials and more fragile results. Black cohosh did not perform better than placebo.
Which plant for menopause and hot flashes?
Sage is the most studied plant outside of isoflavones: in a 4-week trial in 80 women, funded by the extract manufacturer, 59% of women saw their hot flash score drop by at least half, compared to 27% with placebo in the main analysis.
Are menopause supplements as effective as hormone therapy?
No. According to the North American Menopause Society, hormone therapy remains the most effective treatment for hot flashes. In a pooled analysis of 3 trials, low-dose estradiol reduced them by 2.4 more per day than placebo. The choice of treatment is made with your doctor.
What to take during menopause without hormones?
Several non-hormonal medications have solid trials, such as certain antidepressants, gabapentin or fezolinetant, as well as cognitive-behavioral therapy and clinical hypnosis. Your doctor can help you choose.
Is black cohosh effective?
In a Cochrane review of 16 trials and 2,027 women, it performed no better than placebo on hot flash frequency or symptom scores. Liver damage has also been reported, with disputed causality.
Is kudzu effective for menopause?
Data are scarce. In a 4-week trial in 50 women with a root extract, the symptom score decreased, but without a placebo group, and an older trial with a root preparation had not shown net benefit. Kudzu contains isoflavones and is not recommended in case of a history of breast cancer, hormone-dependent disorder, pregnancy or breastfeeding.
Can you take phytoestrogens after breast cancer?
Not without the oncologist's approval. Trials on phytoestrogens most often excluded women who had breast cancer, and phytoestrogen supplements are not recommended in case of personal or family history.
Which supplement for sleep during menopause?
Melatonin improved subjective sleep quality in menopausal women who already slept poorly, according to a review of 24 studies, but not in a 3-month trial at 10 mg in 41 healthy women already sleeping poorly.
Which supplement for mood during menopause?
Saffron improved psychological symptoms more than placebo, with 33% less anxiety and 32% fewer depressive symptoms compared to baseline, in 12 weeks in 86 perimenopausal women, at 14 mg of extract twice daily. Ashwagandha reduced the overall symptom score in an 8-week trial. Persistent sadness warrants a consultation.
Should you take vitamin D and calcium during menopause?
The combination of calcium and vitamin D reduced fracture risk by 15% and hip fracture risk by 30% in a meta-analysis of 8 trials. Vitamin D alone did not reduce fractures.
How long should you take a menopause supplement?
Most trials last 8 to 12 weeks. If there is no clear improvement by then, there is no point in continuing. Phytoestrogen-based supplements should not be taken indefinitely, as 150 mg of isoflavones per day for 5 years were associated with endometrial hyperplasia.
Sources
The studies cited below were identified via PubMed.
- Avis NE, Crawford SL, Greendale G, et al. Duration of hot flashes during the menopausal transition. JAMA Internal Medicine, 2015;175(4):531-539. DOI
- Carpenter JS, Woods NF, Otte JL, et al. MsFLASH participants' priorities for relief of menopause symptoms. Climacteric, 2015;18(6):859-866. DOI
- Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens and vasomotor symptoms of menopause. Cochrane Database of Systematic Reviews, 2013;2013(12):CD001395. DOI
- North American Menopause Society. 2022 Position Statement of the North American Menopause Society on hormone therapy. Menopause, 2022;29(7):767-794. DOI
- North American Menopause Society. 2023 Position Statement of the North American Menopause Society on nonhormonal treatments. Menopause, 2023;30(6):573-590. DOI
- Guthrie KA, LaCroix AZ, Ensrud KE, et al. Six interventions for hot flashes: pooled analysis. Obstetrics and Gynecology, 2015;126(2):413-422. DOI
- Lederman S, Ottery FD, Cano A, et al. Fezolinetant and moderate to severe hot flashes (SKYLIGHT 1). Lancet, 2023;401(10382):1091-1102. DOI
- Taku K, Melby MK, Kronenberg F, et al. Soy isoflavones and hot flashes: meta-analysis of randomized trials. Menopause, 2012;19(7):776-790. DOI
- Unfer V, Casini ML, Costabile L, et al. Effects on the endometrium of prolonged phytoestrogen treatment. Fertility and Sterility, 2004;82(1):145-148. DOI
- Weaver CM, Martin BR, Jackson GS, et al. Phytoestrogen supplements and bone resorption after menopause. Journal of Clinical Endocrinology and Metabolism, 2009;94(10):3798-3805. DOI
- Kanadys W, Barańska A, Błaszczuk A, et al. Red clover and hot flashes: meta-analysis of randomized trials. Nutrients, 2021;13(4):1258. DOI
- Bihlet AR, Byrjalsen I, Andersen JR, et al. Kudzu root extract: bone, cartilage and menopausal symptoms. Frontiers in Pharmacology, 2021;12:760629. DOI
- Woo J, Lau E, Ho SC, et al. Kudzu root compared to hormone therapy after menopause: randomized trial. Menopause, 2003;10(4):352-361. DOI
- Moradi M, Ghavami V, Niazi A, et al. Effect of Salvia officinalis on hot flashes in postmenopausal women: systematic review and meta-analysis. International Journal of Community Based Nursing and Midwifery, 2023;11(3):169-178. DOI
- Dimpfel W, Chiegoua Dipah GN, Bommer S. Sage extract and menopausal symptoms: randomized placebo-controlled trial. Heliyon, 2021;7(2):e05910. DOI
- Zeidabadi A, Yazdanpanahi Z, Dabbaghmanesh MH, et al. Sage extract, hot flashes, night sweats and sleep after menopause. Journal of Family Medicine and Primary Care, 2020;9(2):1086-1092. DOI
- Bommer S, Klein P, Suter A. First evidence of safety and efficacy of sage in postmenopausal women with hot flashes. Advances in Therapy, 2011;28(6):490-500. DOI
- Heyerick A, Vervarcke S, Depypere H, et al. Standardized hop extract and menopausal disorders: placebo-controlled trial. Maturitas, 2006;54(2):164-175. DOI
- Erkkola R, Vervarcke S, Vansteelandt S, et al. Standardized hop extract and menopausal disorders: a pilot crossover trial. Phytomedicine, 2010;17(6):389-396. DOI
- Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews, 2012;2012(9):CD007244. DOI
- Brown AC. Hepatotoxicity related to herbs and dietary supplements: online table of published cases. Food and Chemical Toxicology, 2017;107(Pt A):472-501. DOI
- Teschke R, Schulze J, Schwarzenboeck A, et al. Hepatotoxicity of herbal plants: search for alternative causes in suspected cases. European Journal of Gastroenterology and Hepatology, 2013;25(9):1093-1098. DOI
- Thevi T, De S, Soe HHK. Evening primrose oil and menopausal hot flashes: systematic review and meta-analysis. Journal of Menopausal Medicine, 2024;30(3):127-134. DOI
- Farzaneh F, Fatehi S, Sohrabi MR, Alizadeh K. Effect of oral evening primrose oil on menopausal hot flashes: randomized trial. Archives of Gynecology and Obstetrics, 2013;288(5):1075-1079. DOI
- Winther K, Rein E, Hedman C. Pollen extracts and hot flashes: randomized placebo-controlled trial. Climacteric, 2005;8(2):162-170. DOI
- Acquarulo EL, Hernandez EC, Kodzodziku F, Nemec EC. Efficacy of a purified pollen extract on vasomotor symptoms: systematic review and meta-analysis. Menopause, 2024;31(2):154-159. DOI
- Lopresti AL, Smith SJ. Saffron extract and perimenopausal symptoms: placebo-controlled trial. Journal of Menopausal Medicine, 2021;27(2):66-78. DOI
- Kashani L, Esalatmanesh S, Eftekhari F, et al. Saffron, depression and postmenopausal hot flashes: placebo-controlled trial. Archives of Gynecology and Obstetrics, 2018;297(3):717-724. DOI
- Gopal S, Ajgaonkar A, Kanchi P, et al. Ashwagandha root extract in perimenopause: a placebo-controlled trial. Journal of Obstetrics and Gynaecology Research, 2021;47(12):4414-4425. DOI
- Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-related hepatic injury: a case series. Liver International, 2020;40(4):825-829. DOI
- Lee MS, Shin BC, Yang EJ, et al. Maca (Lepidium meyenii) for the treatment of menopausal symptoms: a systematic review. Maturitas, 2011;70(3):227-233. DOI
- Brooks NA, Wilcox G, Walker KZ, et al. Maca, psychological symptoms, and sexual function after menopause. Menopause, 2008;15(6):1157-1162. DOI
- Treister-Goltzman Y, Peleg R. Melatonin and health in postmenopausal women: a systematic review. Journal of Pineal Research, 2021;71(2):e12743. DOI
- Amstrup AK, Rejnmark L. Melatonin, blood pressure, and quality of life in postmenopausal women: a randomized trial. Complementary Therapies in Medicine, 2024;81:103026. DOI
- Weaver CM, Alexander DD, Boushey CJ, et al. Calcium and vitamin D supplementation and fracture risk: an updated meta-analysis. Osteoporosis International, 2016;27(1):367-376. DOI
- Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes and Endocrinology, 2018;6(11):847-858. DOI
- de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. International Journal of Dermatology, 2021;60(12):1449-1461. DOI
- North American Menopause Society. 2020 position statement of the North American Menopause Society on genitourinary syndrome of menopause. Menopause, 2020;27(9):976-992. DOI
- Park H, Qin R, Smith TJ, et al. Double-blind, placebo-controlled trial of magnesium supplements against menopausal hot flashes. Menopause, 2015;22(6):627-632. DOI



